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Enhanced External Counterpulsation Improves 
Endothelial Function in Patients With Coronary Artery 
Disease 
Pier0 0. Bonetti. Gregory W. Barsness, Paul C. Keelan, Theresa I. Schnell, Geralyn M. 
Pumper, David R. Holmes, Jr., Stuari T. Higano, Amir Lerman, Mayo Clinic, Rochester, 
MN 
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829-l Combined Intense Lifestyle and Pharmacologic Lipid 
Treatment Further Reduce Coronary Events and 
Myocardial Perfusion Abnormalities Compared to Usual 
Care Cholesterol Lowering Drugs in Coronary Artery 
Disease 
Stefano Sdrinaola, Keiichi Nakagawa, Yuko Nakagawa, Wamique S. Yusuf, Fernando 
Boccalandro, Nirar Mullani, Mary Haynie, Mary Jane Hess, K. Lance Gould, The 
Weatherhead P.E.T. Center, University of Texas Medical School Houston, Houston, TX 
Background: Lifestyle and lipid drugs separately benefit Coronary Artery Disease (CAD). 
Objective: Determine if combined intense lifestyle and pharmacologic lipid treatment 
reduce myocardial perfusion abnormalities and coronary events versus usual care cho- 
lesterol lowering drugs and whether perfusion changes predict outcomes. 
Methods: 409 patients with CAD and myocardial perfusion imaging by dipyridamole PET 
at baseline and after 2.6 years had quantitative size/severity of perfusion defects mea- 
sured objectively by automated software with complete follow-up on all patients for 5 
more years for revascularization. non fatal myocardial infarction or cardiac death. 
Patients were categorized blindly by prospective predefined criteria as Poor treatment 
without diet or lipid drugs, or smoking; Moderate treatment on AHA diet and lipid lowering 
drugs or on strict low fat diet (~10% of calories) without lipid drugs; Maximal treatment 
with diet ~10% of calories as fat, regular exercise and lipid active drugs dosed to target 
goals of LDL 1 .Pmmol/L (45 mg/dl) and triglycerides < 1.1 mmol/L (100 mgidl). 
Results: Over 5 years, coronary events occurred in 6.6%, 20.3% and 30.6% of patients 
on Maximal, Moderate and Poor treatment respectively (p= 0.001). Size/severity of perfu- 
sion abnormalities significantly decreased for Maximal and increased for Moderate and 
Poor treatment (p=O.O03 and 0.0001). Combined intense life style change plus lipid 
active drugs and severity/change of perfusion abnormalities independently predicted car- 
diac events. 
Background: Enhanced external counterpulsation (EECP) is a non-Invasive procedure 
that reduces symptoms and improves exercise tolerance in patients with coronary artery 
disease ICAD). However. the mechanisms bv which this techniaue exerts its benefit are 
unclear. This study was designed to investigate the effect of EECP on endothelial func- 
tion. as measured bv Reactive Hvoeremia Perioheral Arterial Tonometrv lRH-PAT), a ~. , \ 
novel, non-invasive technique to assess peripheral microvascular endothelial function in 
the finger. Methods: 23 patients with symptomatic CAD despite optimal medical therapy 
(mean age 66 years, mean CCS class 3.3) underwent a 35hour EECP course over 7 
weeks. R&PAT measurements were performed before and after the Lrst, a mid-course, 
and the last EECP session. In addition, RH-PAT response and functional status were 
assessed one month after EECP treatment. RH-PAT index, a measure of reactive hyper- 
emia, was calculated as the ratio of the digital pulse volume during the first minute of 
reactive hyperemia divided by that at rest. Results: Average CCS class was significantly 
lower immediately and one month after the course of EECP (3.3 vs. 2.4 vs. 2.3, pcO.05). 
As shown in the figure, EECP increased RH-PAT index immediately and at 1 month fol- 
low-up. Conclusion: EECP is associated with improvement in endothelial function which 
Conclusions: Intense life style and pharmacologic lipid treatment 
reduce size/severity of myocardial perfusion abnormalities and cardiac 
may serve as a potential mechanism contributmg to the symptomatic benefit of EECP in 
events compared to usual-care cholesterol lowering drugs. Perfusion changes parallel 
patients with CAD. 
treatment intensity and predict clinical outcomes. 
4.15p.m. 
4:45 pm. 
829-2 Clopldogrel Inhibits Exercise-Induced lschemia and 
Platelet Activation in Stable Coronary Artery Disease 
Eileen E. Mackie, lain Thomson, Mandy Dawson, Allison McKenzie, Stewarf W. Hillis, 
University of Glasgow, Glasgow, United Kingdom, Western Infirmary. Glasgow, United 
Kingdom 
Background:Exercise stimulates coagulation, and thrombocytosis and may trigger the 
clinical presentation of acute coronary syndrome. Aspirin provides little protection against 
exercise induced platelet activation in normal subjects however the effects in coronary 
artery disease (CAD) are controversial. Hypothesis: Clopidogrel inhibits platelet activa- 
tion and provides additional benefits over aspirin in the prevention of exercise induced 
haemostatic changes Methods: 21 patients with CAD awaiting Percutaneous Coronary 
Intervention performed two Bruce protocol exercise tests while receiving l)Aspirin 75mg 
only and 2)aspirin 75mg+clopidogrel 75mg (300mg loading dose+7 days of 75mg). Blood 
sampling was performed pre, immediately post and 30 minutes post exercise. Platelet 
activation was assessed using flow cytometry. CDBP(p-selectin) and antifibrinogen anti- 
body were used to assess platelet activation at rest and in response to ADP and Epi- 
nephrine. All patients performed an exercise test prior to the study for familiarisation and 
samples were blinded for analysis. Results: Data are expressed as mean (SD) or median 
(Interquartile range) when non-parametric test was used. Exercise time increased 
(488(112)seconds to 587(129)seconds p=O.O04) and exercise induced ST depression 
was reduced (-iBmm(O.9), -1.0(0.6) p=O.O4) on aspirin/clopidogrel compared to aspirin 
alone. Anti-fibrinogen antibody binding was reduced at rest(ll.2.%(3.4.22.9), 
3.8%(1.1,5.8), p=O.O7) as was serum fibrinogen (2.98(2.5,3.3), 2.53(2.24,2.9) 
p=O.Od)with the addition of clopidogrel. Clopidogrel abolished the platelet response to 
ADP at all stages of exercise, however most markedly immediately post exercise. 
(%CD62 42.9(38.2,61.4). 20.5 (l&4,32.9) p=O.O08, %Anti-fibrinogen 78.0 (54.2, 91.8.) to 
37.2(20.6, 52.2) p=O.O09). Conclusion: Clopidogrel improves functional capacity and 
exercise induced ST changes as well as reducing platelet activation. This suggests that 
even in stable angina, superimposed thrombus may be an important factor in precipitat- 
ing ischaemia. requiring more aggressive anti-platelet therapy than aspirin alone. 
829-4 Preserved Benefit of Enhanced External 
Counterpulsation in End Stage lschemic Heart Disease 
William E. Lawson, Gregory W. Barsness, Elizabeth D. Kennard. IEPR Investigators, 
SUNY Stony Brook, Stony Brook. NY, University of Pinsburgh School of Public Health, 
Pinsburgh, PA 
Background: Enhanced External Counterpulsation (EECP) is a non-invasive device 
effective for angina in coronary (CAD) patients (pts). EECP is used in pts refractory to 
medicine who are poor candidates for angioplasty (PCI) or bypass (CABG). Whether 
prior PCI or CABG, or when EECP is begun, effects immediate benefit or durability of 
effect is unknown. 
Methods: The IEPR is a prospective. sequential registry characterizing and followmg 
angina pts treated with EECP. Pts with prior PCI or CABG are included. The demograph- 
ics, immediate and sustained (I year) outcomes with prior PCI alone (PC1 group) were 
compared to those with prior CABG (CABG group). 
Results: There were 252 PCI pts and 947 CABG (69.2% prior PCI) pts. The CABG pts 
were older (66.3 f 10.3 vs 63.7 + 11.6 years; pcO.O05), more males (76.8 vs 68.3%: 
pcO.O05), longer duration of CAD (12.5 i 7.9 vs 6.0 * 6.0 years; p<O.OOi). more infarcts 
(72.2 vs 62.7%; p<O.O05), more heart failure (33.7 vs 26.7%; pcO.Ol), more multivessel 
CAD (90.9 vs 47.3%; p<O.OOl), and a lower ejection fraction (45.1 * 13.8 vs 49.0 * 14.8; 
pcO.001). Only 9.9% of the CABG group were revascularization candidates versus 
20.4% of the PCI group (p<O.OOl). Baseline CCS angina class was worse in the CABG 
group (pcO.01). PCI vs CABG group pts received EECP a mean of 32.5 * 10.3 vs 33.1 * 
10.3 hrs; incomplete rate was higher in the PCI group, 11.9 vs 7.0 % (p<O.Ol). There 
were no differences in immediate major (death, unstable angina, MI, CHF, CABG or PCI 
) or minor (musculoskeletal or skin) events. Angina decreased 21 angina class in 69.9 % 
of PCI and 71.4% of CABG pts: p=NS. At one year 74.4% of PCI and 74.2% of CABG pts 
had no angina or were in CCS class l/II; 69.9% of PCI and 70.0% of CABG pts main- 
tained initial reduction in angina. No excess major events or hospitalizations were noted 
at 1 year in the CABG group. 
Conclusion: Similar treatment success and durability of benefit, with similar event rates 
and mortality, are seen after treatment with EECP in pts previously treated with PCI or 
CABG. This benefit is demonstrated despite CABG pts being older, with more extensive 
CAD and prior infarcts, more heart failure, and more severe angina. EECP retains its 
effectiveness, used as a treatment of last resort for angina. 
